OOIR: Observatory of International Research

Papers

(The H4-Index of Digestive and Liver Disease is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO	78
Suppression of high-fat diet-induced obesity-associated liver mitochondrial dysfunction by docosahexaenoic acid and hydroxytyrosol co-administration	75
Diagnosing chronic atrophic gastritis by gastroscopy using artificial intelligence	66
Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: A working hypothesis	66
Safety and efficacy of remimazolam in high risk colonoscopy: A randomized trial	65
Systemic inflammation as fuel for acute liver injury in COVID-19	61
COVID 19 and liver: An A–Z literature review	61
Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis	57
From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: Pathogenesis and impact of current therapies	56
COVID-19 pandemic perception in adults with celiac disease: an impulse to implement the use of telemedicine	54
Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver	51
Impact of the COVID-19 pandemic on Gastroenterology Divisions in Italy: A national survey	48
Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map	47
Foreign body and caustic ingestions in children: A clinical practice guideline	46
Antioxidant activity of Hydroxytyrosol and Vitamin E reduces systemic inflammation in children with paediatric NAFLD	45
Clinical characteristics of coronavirus disease (COVID-19) patients with gastrointestinal symptoms: A report of 164 cases	44
Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review	43
Intestinal ischemia in the COVID-19 era	42
Italian Clinical Practice Guidelines on Cholangiocarcinoma – Part I: Classification, diagnosis and staging	40
Impact of COVID-19 outbreak on clinical practice and training of young gastroenterologists: A European survey	40
COVID-19 and intestinal inflammation: Role of fecal calprotectin	39
Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function	37
Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population	36
Italian Clinical Practice Guidelines on Cholangiocarcinoma – Part II: Treatment	36
The gut–brain axis in irritable bowel syndrome and inflammatory bowel disease	36

Furin inhibits epithelial cell injury and alleviates experimental colitis by activating the Nrf2-Gpx4 signaling pathway	35
COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data	33
COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)	33
Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection	32
Proton pump inhibitor therapy reverses endoscopic features of fibrosis in eosinophilic esophagitis	31
Gastritis: The clinico-pathological spectrum	31